Adverse health events were comparable to placebo in client-owned dogs1*
Cases of vomiting, diarrhea and lethargy resolved without treatment1
*Other than pruritus and alopecia, which were substantially more common in dogs receiving placebo.1
†Occurrence calculated on a per-case basis—no matter how many observations of the same abnormal health event a dog had, it contributed one observation to the occurrence calculation.1
Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.
Reference: 1. Data on file, Study Report No. C961R-US-13-051, Zoetis LLC.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
Zoetis Services LLC. All rights reserved. CYT-00090